Effects of quercetin on inflammation in COPD
Effects of Quercetin on the Oxidative Stress and Inflammatory Markers in COPD Phase II
This study is testing if taking quercetin can help reduce inflammation and oxidative stress in people with COPD.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Temple University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06003270 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of quercetin supplementation on inflammation and oxidative stress in patients with chronic obstructive pulmonary disease (COPD). The study involves a small cohort of participants, with some receiving 1000 mg of quercetin daily, others receiving 500 mg, and a control group receiving a placebo. The aim is to determine if quercetin can effectively reduce markers of inflammation and oxidative stress, which are significant contributors to the progression of COPD. By exploring this alternative treatment, the study seeks to provide insights into potentially safer and more effective management options for COPD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 40 to 80 with a diagnosis of COPD and specific lung function criteria.
Not a fit: Patients with known allergies to quercetin or those with primary asthma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new, well-tolerated treatment option for patients with COPD that may reduce inflammation and improve lung function.
How similar studies have performed: While the use of quercetin in COPD is a novel approach, preclinical studies have shown promising results regarding its antioxidant and anti-inflammatory properties.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with COPD, 40 - 80 yrs of age * Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70 * Both active and ex-smokers with at least 10 pack-years history of smoking * COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period Exclusion Criteria: * Known allergy/sensitivity to quercetin * Subjects with primary current diagnosis of asthma * Upper respiratory tract infection within two weeks of the screening visit * Acute bacterial infection requiring antibiotics within two weeks of screening * Emergency treatment or hospitalization within one month of screening for any reasons * Unwillingness to stop flavonoid supplementation * Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener * Daily warfarin or cyclosporine (Neoral, Sandimmune) * Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period * Lung cancer history or undergoing chemo- or radiation therapy * Inflammatory bowel disease * Women of child-bearing age and unwilling to take pregnancy test * Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study. * Pregnant or lactating mothers
Where this trial is running
Philadelphia, Pennsylvania
- Nathaniel Marchetti — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Nathaniel Marchetti — Temple University
- Study coordinator: Umadevi Sajjan
- Email: uma.sajjan@temple.edu
- Phone: 2157077139
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.